Identification of Chaetocin as a Potent non-ROS-mediated Anticancer Drug Candidate for Gastric Cancer
Xinwen Liao, Yaqiong Fan, Jihuan Hou, Xiong Chen, Xiaolin Xu, Yifan Yang, Jinying Shen, Panying Mi, Xiaohua Huang, Wenqing Zhang, Hanwei Cao, Xiaoting Hong, Tianhui Hu, Yan-yan Zhan
Journal:Journal of Cancer
IF:3.18
DOI:10.7150/jca.32803
PMID:31333785
Published:2019-06-09
research field:肿瘤学药理学细胞生物学
Abstract
Chaetocin, a natural product extracted from Chaetomium species, possesses anticancer effects in several kinds of tumors. However, it remains unclear whether the potential indication for chaetocin could also include human gastric cancer. We found here that chaetocin induced caspase-dependent and -independent apoptosis in human gastric cancer cell lines, which greatly depended on BID-mediated AIF translocation. Despite not increasing the intercellular ROS levels in gastric cancer cells, chaetocin did cause a reduction in mitochondrial membrane potential probably through its regulation on the expression of Bcl-2 and BAX. Chaetocin could also induce autophagy in gastric cancer cells; blocking autophagy by chloroquine enhanced the cytotoxicity of chaetocin. Chaetocin was further found to suppress the growth of gastric cancer xenograft in nude mice. Therefore, our study provides first evidence that chaetocin has an anticancer efficacy against gastric cancer and the combined use of chaetocin with autophagy inhibitors may enhance the therapeutic effect for gastric cancer. As chronic and exorbitant ROS levels instigate drug resistance, chaetocin, which eradicates gastric cancer cells without increasing ROS levels, may initiate a new line of non-ROS-mediated anti-tumor strategy.
本文使用的Yeasen产品


